Single Cell Genomics Markets 2027–2031

Single Cell Genomics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031

Global forecasts by analyte, product, workflow, end user and field, for 14 countries and regions, with 33 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Single cell genomics is becoming an industrial data business. Diversified tools companies have bought most of the independent platform makers, the market leader is betting on a new spatial platform, and the biggest new buyers are pharmaceutical and AI companies building perturbation datasets to train models of the cell. The market grows from $3,860 million in 2026 to $9,200 million in 2031, at 19.0% a year. Multi-omic assays gain the most share, and Biopharma overtakes academic research as the largest customer.

Market Size 2026: USD $3.86B Market Size 2031: USD $9.2B CAGR: 19.0%

Situation Analysis: what is really happening

• Tools companies have bought the platform makers. Waters completed its combination with BD's Biosciences business, including BD Rhapsody, and QIAGEN bought Parse Biosciences for about $225 million.
• The leader is between product cycles. 10x Genomics' instrument revenue fell to $7.7 million in the second quarter of 2026, and it began shipping its Atera spatial platform in September.
• Perturbation data is the new demand. Illumina's Billion Cell Atlas, Xaira's X-Cell model and Biohub's $1.8 billion Virtual Biology Initiative consume reagents by the million cells.
• Patents shape the market. 10x Genomics and Roche sued Illumina, 10x won a jury verdict against Parse and sued Element Biosciences.
• Multi-omics moves to the centre. Multi-omic assays grow 26.6% a year, from 20.5% to 28.0% of the market.
• Biopharma overtakes Research. Biopharma rises from 37.5% to 40.5% of spending and Research falls from 45.5% to 36.5%, while clinical use grows fastest at 28.1% a year.

Company Analysis: who is positioned, who is exposed

• 10x Genomics: Holds the largest installed base and is betting its growth on the Atera spatial platform.
• Waters (BD Rhapsody), QIAGEN (Parse) and Illumina: Diversified tools companies that now own most of the competing platforms.
• Illumina, Biohub, Arc Institute and Tahoe Therapeutics: Build the very large perturbation datasets driving new demand.
• Xaira Therapeutics and NVIDIA: Turn single-cell data into AI models of the cell.
• Mission Bio, BioSkryb and Standard BioTools: Smaller specialists facing a choice between clinical niches and consolidation.

In all, 33 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will single cell genomics grow, and which analytes and workflow steps gain share?
• How much demand will perturbation screens and AI virtual cell models create?
• Will Biopharma overtake academic research as the largest customer, and when?
• How will consolidation and patent litigation change which platforms customers buy?
• When will single-cell methods enter routine clinical use?
• How large is each country market, and how fast is China growing?

What's inside

• 264 pages, 23 chapters, 59 tables and 50 figures
• Forecasts for 2027–2031 from a 2026 base year, by analyte, product, workflow, end user and field, for 14 countries and regions
• Single-cell platforms and technologies, spatial biology and multi-omics, and applications by field
• Biopharma, perturbation screens and AI virtual cells, data analysis, clinical translation and research funding, and China and Asia-Pacific
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 33 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Single-cell platform and reagent companies: plan products and pricing for a market led by biopharma and data-scale buyers.
• Business development and strategy teams: size perturbation, spatial and clinical opportunities and track consolidation.
• Investors and analysts: assess growth, instrument demand and patent risk.
• Pharma, AI companies and core facilities: plan single-cell capacity for drug discovery and model building.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.